Search: onr:"swepub:oai:DiVA.org:liu-202318" >
Ixazomib, Lenalidom...
-
Partanen, AnuKuopio Univ Hosp, Finland
(author)
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
- Article/chapterEnglish2024
Publisher, publication year, extent ...
-
MDPI,2024
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-202318
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-202318URI
-
https://doi.org/10.3390/cancers16051024DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:238473382URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:155240493URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Funding Agencies|BMS
-
Scarce data exist on double maintenance in transplant-eligible high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients. This prospective phase 2 study enrolled 120 transplant-eligible NDMM patients. The treatment consisted of four cycles of ixazomib-lenalidomide-dexamethasone (IRD) induction plus autologous stem cell transplantation followed by IRD consolidation and cytogenetic risk-based maintenance therapy with lenalidomide + ixazomib (IR) for HR patients and lenalidomide (R) alone for NHR patients. The main endpoint of the study was undetectable minimal residual disease (MRD) with sensitivity of <10-5 by flow cytometry at any time, and other endpoints were progression-free survival (PFS) and overall survival (OS). We present the preplanned analysis after the last patient has been two years on maintenance. At any time during protocol treatment, 28% (34/120) had MRD < 10-5 at least once. At two years on maintenance, 66% of the patients in the HR group and 76% in the NHR group were progression-free (p = 0.395) and 36% (43/120) were CR or better, of which 42% (18/43) had undetectable flow MRD <10-5. Altogether 95% of the patients with sustained MRD <10-5, 82% of the patients who turned MRD-positive, and 61% of those with positive MRD had no disease progression at two years on maintenance (p < 0.001). To conclude, prolonged maintenance with all-oral ixazomib plus lenalidomide might improve PFS in HR patients.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Waage, AndersSt Olavs Hosp, Norway
(author)
-
Peceliunas, ValdasVilnius Univ Hosp, Lithuania
(author)
-
Schjesvold, FredrikOslo Univ Hosp, Norway; Univ Oslo, Norway
(author)
-
Anttila, PekkaUniv Helsinki, Finland
(author)
-
Saeily, MarjaanaOulu Univ Hosp Hematol, Finland
(author)
-
Uttervall, KatarinaKarolinska Institutet,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden
(author)
-
Putkonen, MerviTurku Univ Hosp, Finland
(author)
-
Carlson, KristinaUppsala Univ Hosp, Sweden
(author)
-
Haukas, EinarStavanger Univ Hosp, Norway
(author)
-
Sankelo, MarjaTampere Univ Hosp Hematol, Finland
(author)
-
Szatkowski, DamianFoerde Cent Hosp, Norway
(author)
-
Hansson, MarkusSkane Univ Hosp, Sweden
(author)
-
Marttila, AnuKymenlaakso Cent Hosp, Finland
(author)
-
Svensson, RonaldRegion Östergötland, Hematologiska kliniken US(Swepub:liu)ronsv17
(author)
-
Axelsson, PerHelsingborg Hosp, Sweden
(author)
-
Lauri, BirgittaSunderby Hosp, Sweden
(author)
-
Mikkola, MaijaPaijat Hame Cent Hosp, Finland
(author)
-
Karlsson, ConnyHalland Hosp, Sweden
(author)
-
Abelsson, JohannaUddevalla Cent Hosp, Sweden
(author)
-
Ahlstrand, ErikOrebro Univ Hosp, Sweden
(author)
-
Sikioe, AnuCent Finland Cent Hosp, Finland
(author)
-
Klimkowska, MonikaKarolinska Univ Hosp, Sweden
(author)
-
Matuzeviciene, RedaVilnius Univ Hosp, Lithuania; Vilnius Univ, Lithuania
(author)
-
Fenstad, Mona HoysaeterSt Olavs Hosp, Norway
(author)
-
Ilveskero, SorellaUniv Helsinki, Finland
(author)
-
Pelliniemi, Tarja-TerttuFimlab Labs Ltd, Finland
(author)
-
Nahi, HarethKarolinska Univ Hosp Huddinge, Sweden
(author)
-
Silvennoinen, RaijaUniv Helsinki, Finland
(author)
-
Kuopio Univ Hosp, FinlandSt Olavs Hosp, Norway
(creator_code:org_t)
Related titles
-
In:Cancers: MDPI16:52072-6694
Internet link
Find in a library
-
Cancers
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Partanen, Anu
-
Waage, Anders
-
Peceliunas, Vald ...
-
Schjesvold, Fred ...
-
Anttila, Pekka
-
Saeily, Marjaana
-
show more...
-
Uttervall, Katar ...
-
Putkonen, Mervi
-
Carlson, Kristin ...
-
Haukas, Einar
-
Sankelo, Marja
-
Szatkowski, Dami ...
-
Hansson, Markus
-
Marttila, Anu
-
Svensson, Ronald
-
Axelsson, Per
-
Lauri, Birgitta
-
Mikkola, Maija
-
Karlsson, Conny
-
Abelsson, Johann ...
-
Ahlstrand, Erik
-
Sikioe, Anu
-
Klimkowska, Moni ...
-
Matuzeviciene, R ...
-
Fenstad, Mona Ho ...
-
Ilveskero, Sorel ...
-
Pelliniemi, Tarj ...
-
Nahi, Hareth
-
Silvennoinen, Ra ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Cancers
- By the university
-
Linköping University
-
Karolinska Institutet